News
The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...
ePoster Title: “EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study” ...
Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSV” ...
Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation.
The RSV F protein is a trimer in two different forms: a metastable, pre-fusion form (pre-F) and stable post-fusion form (post-F), as outlined in Figure 1.
Beyfortus-maker AstraZeneca enters RSV vaccine race with $800M Icosavax acquisition S-337395 is designed to inhibit the activity of the L protein, which is required for the virus to replicate.
In the hMPV F protein, Zhu didn't find the same patch of repellant molecules - instead, he used a strong chemical bond as a "brute force" solution to hold the protein together.
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorised mRNA-based shot for ...
The RSV vaccine consists of inactivated RSV proteins. Once you get the shot, the inactivated protein signals your immune system to recognize the actual virus if it were to enter into your body.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results